1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Measures of repeatability for automatically segmented volumes
BraTumIA Version RC (95% CI), mL %RC (95% CI)
1.2 2.0 1.2 2.0
Enhancing 6.9 (4.9–10) 5.2 (3.7–7.5) 46% (33%–67%) 39% (28%–57%)
Edema 24 (17–35) 30 (21–43) 31% (22%–45%) 36% (26%–52%)
Non-enhancing 2.1 (1.5–3.1) 2.0 (1.4–2.8) 95%^{^a} (68%–140%) 116%^{^a} (84%–174%)
Necrotic 3.1 (2.2–4.5) 2.0 (1.4–2.9) 87% (62%–130%) 81% (58%–117%)
Total tumor-related abnormality 25 (18–36) 31 (22–44) 26% (18%–37%) 32% (22%–47%)
Total non-enhancing tumor-related abnormality 24 (17–34) 30 (21–43) 30% (21%–44%) 35% (25%–51%)
Non-enhancing non-necrotic tumor-related abnormality 24 (17–35) 29 (21–42) 31% (22%–44%) 36% (25%–51%)
White matter 40 (28–58) 47 (33–67) 7.1% (5.1%–10%) 8.3% (5.9%–12%)
Gray matter 46 (33–67) 45 (32–65) 7.6% (5.3%–11%) 7.3% (5.1%–10%)
↵a N = 19 because of average non-enhancing volume of 0 for 1 patient.